SiccaNova Therapeutics Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$8.8M
- Investors
-
6
SiccaNova Therapeutics General Information
Description
Developer of a small-molecule drug designed to target candidates with dryness-related medical conditions. The company uses advanced low-molecular-weight compounds that address unmet therapeutic needs in dryness pathology, enabling the dryness-related disease therapeutics market to access novel treatment options.
Contact Information
Website
www.siccanova.comCorporate Office
- 2-5-1 Azuma, Tsukuba Startup Park
- 2nd Floor
- Tsukuba, Ibaraki 305-0031
- Japan
Corporate Office
- 2-5-1 Azuma, Tsukuba Startup Park
- 2nd Floor
- Tsukuba, Ibaraki 305-0031
- Japan
SiccaNova Therapeutics Timeline
SiccaNova Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series A) | 03-Sep-2026 | $8.8M | Completed | Startup | ||
| 2. Early Stage VC | 23-Oct-2025 | Completed | Startup | |||
| 1. Seed Round | 17-May-2022 | $1.62M | $1.62M | Completed | Startup |
SiccaNova Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Class B2 Preferred | ||||||||
| Class B1 Preferred | ||||||||
| Class A Preferred | 20,000,000 | $0.07 | $0.07 | 1x | $0.07 | 18.18% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
SiccaNova Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
SiccaNova Therapeutics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| JIC Venture Growth Investments | Venture Capital | Minority | ||
| Joyo Capital Partners | Corporate Venture Capital | Minority | ||
| MPower Partners | Venture Capital | Minority | ||
| Red Capital (Japan) | Venture Capital | Minority | ||
| Shichijushichi Capital | Venture Capital | Minority |
SiccaNova Therapeutics FAQs
-
When was SiccaNova Therapeutics founded?
SiccaNova Therapeutics was founded in 2022.
-
Where is SiccaNova Therapeutics headquartered?
SiccaNova Therapeutics is headquartered in Tsukuba, Japan.
-
What is the size of SiccaNova Therapeutics?
SiccaNova Therapeutics has 2 total employees.
-
What industry is SiccaNova Therapeutics in?
SiccaNova Therapeutics’s primary industry is Drug Discovery.
-
Is SiccaNova Therapeutics a private or public company?
SiccaNova Therapeutics is a Private company.
-
What is the current valuation of SiccaNova Therapeutics?
The current valuation of SiccaNova Therapeutics is .
-
What is SiccaNova Therapeutics’s current revenue?
The current revenue for SiccaNova Therapeutics is .
-
How much funding has SiccaNova Therapeutics raised over time?
SiccaNova Therapeutics has raised $11.1M.
-
Who are SiccaNova Therapeutics’s investors?
JIC Venture Growth Investments, Joyo Capital Partners, MPower Partners, Red Capital (Japan), and Shichijushichi Capital are 5 of 6 investors who have invested in SiccaNova Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
